VIDEO | Proactive Investors Interview, Phase 2 Clinical Trial Posted on April 7th, 2022 . Updated on April 7th, 2022 by Amplia TherapeuticsIn this video, Amplia CEO and MD, Dr John Lambert, explains what's to come in the Phase 2 clinical trial for our Focal Adhesion Kinase (FAK) inhibitor, AMP945, in first-line patients with advanced pancreatic cancer.